Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children and Adult Participants With Dravet Syndrome (ARGUS Trial)

NCT04462770 is registered in ClinicalTrials.gov with Epygenix as lead sponsor.

NCT NCT04462770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04462770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in Children and Adult Participants With Dravet Syndrome (ARGUS Trial)
Lead sponsor
Epygenix
Phase
Phase 3
Overall status
Recruiting
Start date
September 15, 2020
Completion date
May 31, 2029
Enrollment
150 (estimated)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

dravet syndrome